PE20011113A1 - CONTROLLED ORAL ADMINISTRATION SYSTEM FOR DAILY INGESTION OF CIPROFLOXACINE - Google Patents
CONTROLLED ORAL ADMINISTRATION SYSTEM FOR DAILY INGESTION OF CIPROFLOXACINEInfo
- Publication number
- PE20011113A1 PE20011113A1 PE2001000206A PE2001000206A PE20011113A1 PE 20011113 A1 PE20011113 A1 PE 20011113A1 PE 2001000206 A PE2001000206 A PE 2001000206A PE 2001000206 A PE2001000206 A PE 2001000206A PE 20011113 A1 PE20011113 A1 PE 20011113A1
- Authority
- PE
- Peru
- Prior art keywords
- formulation
- agent
- less
- weight
- ciprofloxacine
- Prior art date
Links
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003405 ciprofloxacin Drugs 0.000 title abstract 2
- 230000037406 food intake Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- 229920003086 cellulose ether Polymers 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA FORMULACION DE LIBERACION CONTROLADA QUE COMPRENDE: a) UNA CANTIDAD EFECTIVA DE CIPROFLOXACINA; b) DE 0,1% A 8 % DE UN AGENTE DE VISCOSIDAD TAL COMO GOMA, ETERES DE CELULOSA DE PREFERENCIA GOMA XANTANO E HIDROXIPROPILCELULOSA Y/O UN AGENTE DE GELACION TAL COMO ALGINATO DE SODIO; c) DE 5% A 15% DE UNA AGENTE GENERADOR DE GAS TAL COMO BICARBONATO DE SODIO, CARBONATO DE CALCIO, CARBONATO DE SODIO Y; d) DE 3% A 15% DE UN AGENTE DE EXPANSION TAL COMO POLIVINILPIRROLIDONA , SIENDO TALES PORCENTAJES CON RELACION AL PESO/PESO DEL COMPUESTO. LA CIPROFLOXACINA SE LIBERA MAS DEL 50% DEL MEDICAMENTO EN MENOS DE 4 HORAS Y MAS DEL 60% DEL MEDICAMENTO EN MENOS DE 8 HORAS. LA FORMULACION COMPRENDE DE 100mg A 1000mg DE CIPROFLOXACINA Y EXCIPIENTES EN LA QUE EL PESO TOTAL DE LA FORMULACION CORRESPONDE A MENOS DE 2000mg. LA FORMULACION ES ADMINISTRADA VIA ORAL Y LA LIBERACION CONTROLADA DE CIPROFLOXACIONA SE PRODUCE EN EL ESTOMAGO O PARTE SUPERIOR DEL INTESTINOIT REFERS TO A CONTROLLED RELEASE FORMULATION THAT INCLUDES: a) AN EFFECTIVE AMOUNT OF CYPROFLOXACIN; b) FROM 0.1% TO 8% OF A VISCOSITY AGENT SUCH AS RUBBER, CELLULOSE ETHERS OF PREFERENCE XANTHANE GUM AND HYDROXYPROPYLCELLULOSE AND / OR A GELING AGENT SUCH AS SODIUM ALGINATE; c) FROM 5% TO 15% OF A GAS GENERATING AGENT SUCH AS SODIUM BICARBONATE, CALCIUM CARBONATE, SODIUM CARBONATE AND; d) FROM 3% TO 15% OF AN EXPANSION AGENT SUCH AS POLYVINYLPYRROLIDONE, SUCH PERCENTAGES IN RELATION TO THE WEIGHT / WEIGHT OF THE COMPOUND. CYPROFLOXACIN IS RELEASED MORE THAN 50% OF THE MEDICINE IN LESS THAN 4 HOURS AND MORE THAN 60% OF THE MEDICINE IN LESS THAN 8 HOURS. THE FORMULATION INCLUDES FROM 100mg TO 1000mg OF CIPROFLOXACIN AND EXCIPIENTS IN WHICH THE TOTAL WEIGHT OF THE FORMULATION CORRESPONDS TO LESS THAN 2000mg. THE FORMULATION IS ADMINISTERED VIA ORAL AND THE CONTROLLED RELEASE OF CIPROFLOXACIONA IS PRODUCED IN THE STOMACH OR UPPER PART OF THE INTESTINE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51788700A | 2000-03-03 | 2000-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20011113A1 true PE20011113A1 (en) | 2001-10-14 |
Family
ID=24061635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000206A PE20011113A1 (en) | 2000-03-03 | 2001-03-01 | CONTROLLED ORAL ADMINISTRATION SYSTEM FOR DAILY INGESTION OF CIPROFLOXACINE |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1263409A1 (en) |
| JP (1) | JP2003525229A (en) |
| KR (1) | KR20030009374A (en) |
| CN (1) | CN1420763A (en) |
| AP (2) | AP2001002084A0 (en) |
| AR (1) | AR032614A1 (en) |
| AU (1) | AU3589701A (en) |
| BG (1) | BG107055A (en) |
| BR (1) | BR0108958A (en) |
| CA (1) | CA2400950A1 (en) |
| CZ (1) | CZ20022883A3 (en) |
| DO (1) | DOP2001000130A (en) |
| EA (1) | EA200200914A1 (en) |
| EC (1) | ECSP013952A (en) |
| EE (1) | EE200200497A (en) |
| GT (1) | GT200100033A (en) |
| HN (1) | HN2001000038A (en) |
| HR (1) | HRP20020715A2 (en) |
| HU (1) | HUP0204417A3 (en) |
| IL (1) | IL151553A0 (en) |
| IS (1) | IS6532A (en) |
| MX (1) | MXPA02008568A (en) |
| NO (1) | NO20024108L (en) |
| NZ (1) | NZ520927A (en) |
| OA (1) | OA12381A (en) |
| PE (1) | PE20011113A1 (en) |
| PL (1) | PL365071A1 (en) |
| SK (1) | SK12542002A3 (en) |
| WO (1) | WO2001064183A1 (en) |
| YU (1) | YU66202A (en) |
| ZA (1) | ZA200206764B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| US20030229101A1 (en) * | 2002-06-06 | 2003-12-11 | Sherman Bernard Charles | Tablets comprising ciprofloxacin hydrochloride |
| DE10351448A1 (en) | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Flavor-containing drug formulations with improved pharmaceutical properties |
| ATE396710T1 (en) * | 2005-07-19 | 2008-06-15 | Ethypharm Sa | GASTRORETENTIVE COMPOSITIONS AND METHOD FOR PRODUCING |
| EP1880722B1 (en) * | 2006-07-19 | 2010-03-17 | Tabuk Pharmaceutical Manufacturing Co. | Pharmaceutical compositions of ciprofloxacin |
| WO2016115253A1 (en) | 2015-01-14 | 2016-07-21 | The Regents Of The University Ofcolordo, A Body Corporate | Insulin mimotopes and methods of using the same |
| US20190070299A1 (en) * | 2016-02-23 | 2019-03-07 | Matripharm International Inc. | Dual-rate release formulation with high drug loading |
| US9820957B2 (en) | 2016-03-24 | 2017-11-21 | The Regents Of The University Of Colorado, A Body Corporate | Methods of treating autoimmunity |
| US11052060B2 (en) | 2018-02-12 | 2021-07-06 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and methods for treating autoimmunity |
| US11013707B2 (en) | 2018-03-23 | 2021-05-25 | The Regents Of The University Of Colorado, A Body Corporate | Administration of oral methyldopa |
| CN109806237A (en) * | 2019-03-13 | 2019-05-28 | 悦康药业集团上海制药有限公司 | A kind of Ciprofloxacin Lactate effervescent tablet and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5096714A (en) * | 1988-06-28 | 1992-03-17 | Hauser-Kuhrts, Inc. | Prolonged release drug tablet formulations |
| JPH0624959A (en) * | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | Medice release solid pharmaceutical preparation of gastric suspending type sustained |
| DE4406424A1 (en) * | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandable dosage forms |
| DE19839057A1 (en) * | 1998-08-28 | 2000-03-02 | Koch Berthold | Purge air controller for a drying device for compressed air |
| EA005767B1 (en) * | 1998-09-14 | 2005-06-30 | Рэнбакси Лабораториз Лимитед | Pharmaceutical composition representing system of controlled delivery of a medicament for oral administration, providing time and local control |
-
2001
- 2001-02-28 HU HU0204417A patent/HUP0204417A3/en unknown
- 2001-02-28 EP EP01908038A patent/EP1263409A1/en not_active Withdrawn
- 2001-02-28 YU YU66202A patent/YU66202A/en unknown
- 2001-02-28 AR ARP010100957A patent/AR032614A1/en not_active Application Discontinuation
- 2001-02-28 MX MXPA02008568A patent/MXPA02008568A/en unknown
- 2001-02-28 EA EA200200914A patent/EA200200914A1/en unknown
- 2001-02-28 AP APAP/P/2001/002084A patent/AP2001002084A0/en unknown
- 2001-02-28 NZ NZ520927A patent/NZ520927A/en unknown
- 2001-02-28 KR KR1020027011441A patent/KR20030009374A/en not_active Ceased
- 2001-02-28 OA OA1200200267A patent/OA12381A/en unknown
- 2001-02-28 CA CA002400950A patent/CA2400950A1/en not_active Abandoned
- 2001-02-28 EE EEP200200497A patent/EE200200497A/en unknown
- 2001-02-28 CN CN01805998A patent/CN1420763A/en active Pending
- 2001-02-28 CZ CZ20022883A patent/CZ20022883A3/en unknown
- 2001-02-28 IL IL15155301A patent/IL151553A0/en unknown
- 2001-02-28 BR BR0108958-7A patent/BR0108958A/en not_active IP Right Cessation
- 2001-02-28 SK SK1254-2002A patent/SK12542002A3/en unknown
- 2001-02-28 HR HRP20020715 patent/HRP20020715A2/en not_active Application Discontinuation
- 2001-02-28 JP JP2001563081A patent/JP2003525229A/en not_active Withdrawn
- 2001-02-28 AU AU35897/01A patent/AU3589701A/en not_active Abandoned
- 2001-02-28 PL PL01365071A patent/PL365071A1/en not_active Application Discontinuation
- 2001-02-28 WO PCT/IB2001/000279 patent/WO2001064183A1/en not_active Ceased
- 2001-02-28 AP APAP/P/2002/002627A patent/AP1485A/en active
- 2001-03-01 GT GT200100033A patent/GT200100033A/en unknown
- 2001-03-01 PE PE2001000206A patent/PE20011113A1/en not_active Application Discontinuation
- 2001-03-01 EC EC2001003952A patent/ECSP013952A/en unknown
- 2001-03-02 HN HN2001000038A patent/HN2001000038A/en unknown
- 2001-03-02 DO DO2001000130A patent/DOP2001000130A/en unknown
-
2002
- 2002-08-23 ZA ZA200206764A patent/ZA200206764B/en unknown
- 2002-08-28 NO NO20024108A patent/NO20024108L/en unknown
- 2002-08-28 IS IS6532A patent/IS6532A/en unknown
- 2002-09-02 BG BG107055A patent/BG107055A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20022883A3 (en) | 2003-04-16 |
| HN2001000038A (en) | 2005-03-23 |
| HUP0204417A3 (en) | 2005-03-29 |
| CN1420763A (en) | 2003-05-28 |
| NO20024108L (en) | 2002-10-25 |
| DOP2001000130A (en) | 2004-03-31 |
| EE200200497A (en) | 2004-02-16 |
| ECSP013952A (en) | 2002-04-23 |
| EA200200914A1 (en) | 2003-02-27 |
| CA2400950A1 (en) | 2001-09-07 |
| PL365071A1 (en) | 2004-12-27 |
| AP1485A (en) | 2005-10-31 |
| JP2003525229A (en) | 2003-08-26 |
| MXPA02008568A (en) | 2003-02-24 |
| ZA200206764B (en) | 2003-03-04 |
| NZ520927A (en) | 2003-06-30 |
| KR20030009374A (en) | 2003-01-29 |
| AP2001002084A0 (en) | 2001-03-31 |
| EP1263409A1 (en) | 2002-12-11 |
| HRP20020715A2 (en) | 2004-12-31 |
| WO2001064183A1 (en) | 2001-09-07 |
| SK12542002A3 (en) | 2003-05-02 |
| AR032614A1 (en) | 2003-11-19 |
| NO20024108D0 (en) | 2002-08-28 |
| AU3589701A (en) | 2001-09-12 |
| GT200100033A (en) | 2001-10-25 |
| HUP0204417A2 (en) | 2003-05-28 |
| BG107055A (en) | 2003-06-30 |
| YU66202A (en) | 2005-09-19 |
| IS6532A (en) | 2002-08-28 |
| OA12381A (en) | 2004-09-06 |
| BR0108958A (en) | 2003-09-30 |
| AP2002002627A0 (en) | 2002-09-30 |
| IL151553A0 (en) | 2003-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR022672A1 (en) | A PHARMACEUTICAL COMPOSITION IN THE FORM OF TABLETS OR CAPSULES THAT CONSTITUTE AN ORAL ADMINISTRATION METHOD OF A DRUG | |
| ES2251494T3 (en) | QUICK ACTION FORMULATION. | |
| SI1898876T1 (en) | Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical presentations | |
| YU19501A (en) | Orally administrated controlled drug delivery system providing temporal and spatial control | |
| BR0113626A (en) | Sustained-Release Formulations for Growth Hormone Secretors | |
| PE20011113A1 (en) | CONTROLLED ORAL ADMINISTRATION SYSTEM FOR DAILY INGESTION OF CIPROFLOXACINE | |
| CO6251259A2 (en) | PHARMACEUTICAL FORMULATIONS OF ESTRIOL IN LOW DOSE | |
| BR0008590A (en) | Polymeric delivery agent, composition, unit dosage form, method for administering a biologically active agent to an animal requiring the agent, method for preparing a composition; it's composed | |
| AR041370A1 (en) | SOLID PHARMACEUTICAL FORMULATIONS THAT INCLUDE TELMISARTAN AND ITS PREPARATION | |
| AR049985A1 (en) | COMBINATION TREATMENT FOR NON-HEMATOLOGICAL MALIGNAL DISEASES | |
| BR9916224A (en) | Oral pharmaceutical dosage form, processes for the manufacture of a fixed dosage form, for the treatment and prophylaxis of gastrointestinal disorders and to prevent gastrointestinal side effects, use of a dosage form, combination, and ampoule packaging | |
| NZ511900A (en) | Sustained release matrix systems for highly soluble drugs | |
| BR0312640A (en) | Formulation against mycoplasma gallisepticum | |
| ES2113136T3 (en) | PHARMACEUTICAL COMPOSITIONS OF GEMFIBROZIL AND PROCEDURE FOR ITS PREPARATION. | |
| MX9704043A (en) | SUSTAINED LIBERATION PHARMACY ASSORTMENT USING A HYDROCOLOID POWDER GUM OBTAINABLE FROM SUPERIOR PLANTS. | |
| UY26176A1 (en) | POLYMORPHIC FORMS OF A AZOBICICLO CITRATE (2,2,2) OCTAN-3-AMINE AND ITS PHARMACEUTICAL COMPOSITIONS. | |
| ES2238497T3 (en) | RIBAVIRINE GRANULATE FOR THE OBTAINING OF FILMED TABLETS. | |
| BR0318167A (en) | controlled release formulation containing a hydrophobic material as the controlled release agent | |
| UY26605A1 (en) | CONTROLLED ORAL ADMINISTRATION SYSTEM FOR DAILY INGESTION OF CIPROFLOXACIN | |
| MD2975F1 (en) | Remedy in the form of gel for rosacea treatment | |
| MD2976F1 (en) | Remedy in the form of gel for acnea treatment | |
| SV2003000335A (en) | CONTROLLED ORAL ADMINISTRATION SYSTEM FOR DAILY INTAKE OF CIPROFLOXACINE | |
| BR0300434A (en) | Oral pharmaceutical composition, used as general antispasmodic smooth muscle with biliary, digestive, urinary and gynecological applications, and in the treatment of moderate to severe intestinal colic, and its use | |
| LT2006062A (en) | Medicinal produkts of elemental sulfur for the treatment of glutathione s transferase related deseases | |
| GT199800053A (en) | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF THE N-PIPERIDINE-5- (4-CHLOROPHENYL) -1- (2,4-DICHLOROPHENYL) -4-METHYLPIRAZOLE-3-CARBOXAMIDE, OF ITS SALES AND DESUSSOLVATES. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |